We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced the closing of an underwritten public offering of 3,565,000 shares of its common stock at a public offering price of $48.50 per share.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced the commencement of a proposed underwritten public offering of $150 million of shares of its common stock.